Nusinersen
As of the edition of 20 October 2026, Nusinersen is an oligonucleotide: marketed, first approved in 2016 (US); acts on SMN2; US protection ends in 2030.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Oligonucleotide
- Brand name
- Spinraza
- First approved
- 23 December 2016 (US)
- Approvals on record
- 10 in 4 regions
- Holder of the most recent approval
- Biogen; 5 holders in all
- Registered trials
- 30, 3 stopped early
- Disease areas
- Nervous system; Inherited and neonatal; Nutrition and metabolism
US protection
US protection ends in 2030.
The last listed US drug-substance patent ends in 2030. The application that gives this date is held by Biogen.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product8 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 8 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Nusinersen.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SMN2 | Survival motor neuron protein | Q16637 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 13 | 6 | 4 | 0 |
| Phase 1 | 5 | 3 | 1 | 1 |
| Phase 2 | 5 | 3 | 1 | 1 |
| Phase 3 | 6 | 4 | 1 | 1 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 30 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Biogen | Originator, Applicant and Lead sponsor of trials | 2016 to now |